Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX460 · 1 trial · 1 indication
Incidence of DLTs and frequency of AEs
Absolute blood levels of total AAT at Month 6
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | Phase 1 begins with dose escalation based on a single infusion of CTX460. |
| Phase 2 | EXPERIMENTAL | Recommended Phase 2 dose of CTX460. |
| Name | Type | Description |
|---|---|---|
| CTX460 | DRUG | CTX460 is a lipid nanoparticle (LNP) formulation of synthetic nucleotide template polymerase (SyNTase) editor for in vivo gene editing of the serine protease inhibitor A1 (SERPINA1) gene in adults with emphysema associated with severe alpha-1 antitrypsin deficiency (AATD). |
Inclusion Criteria: 1. Age: ≥18 and ≤75 years. 2. Able to provide written informed consent. 3. Diagnosis of AATD with PiZZ homozygous genotype. 4. Serum total AAT level \<11µM in the absence of augmentation. 5. Emphysema on a CT scan at screening. 6. A postbronchodilator forced expiratory volume in...
CTX460 is an investigational small molecule developed by CRISPR Therapeutics AG for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can lead to emphysema. It is being studied in adults with emphysema associated with severe AATD and is currently in Phase 1/2 clinical development.
CTX460 targets SERPINA1, the gene that encodes alpha-1 antitrypsin. By acting on SERPINA1, the small molecule is designed to address the underlying deficiency in AATD. The Phase 1/2 trial evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CTX460 in adults with emphysema associated with severe AATD.
CTX460 is being developed by CRISPR Therapeutics AG, which trades under the ticker CRSP. The company is running the clinical program for CTX460 in alpha-1 antitrypsin deficiency, with the compound currently in Phase 1/2 development.
CTX460 is in Phase 1/2 clinical development. It is investigational and is being studied in a single recruiting Phase 1/Phase 2 trial in adults with emphysema associated with severe alpha-1 antitrypsin deficiency. The study has an estimated enrollment of 68 participants.
CTX460 is being studied in trial NCT07850076, titled a trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CTX460 in adults with emphysema associated with severe alpha-1 antitrypsin deficiency. The Phase 1/Phase 2 study is recruiting, is controlled, enrolls an estimated 68 participants, and is conducted in Australia.
CTX460 is being developed for alpha-1 antitrypsin deficiency (AATD), specifically for adults with emphysema associated with severe AATD. The Phase 1/2 trial enrolls participants aged 18 years and older of all sexes and assesses safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of the small molecule.